C. Nasmyth‐Miller

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis

J. Pope, J. Merrill, A. Kivitz, 2017, The Journal of Rheumatology.

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

J. Pope, J. Merrill, M. Bao, 2014, Arthritis care & research.

Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

B. Nashan, Y. Vanrenterghem, F. Vincenti, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

Timothy D. Knab, L. Gibiansky, J. Hernández-Sánchez, 2021, British journal of clinical pharmacology.

Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study

Y. Huang, N. Frey, E. Sokal, 2018, Hepatology.

Association of four DNA polymorphisms with acute rejection after kidney transplantation

K. Lindpaintner, O. Spleiss, L. Essioux, 2008, Transplant international : official journal of the European Society for Organ Transplantation.

The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results

E. Calleja, B. Nashan, Y. Vanrenterghem, 2005 .

THE USE OF DACLIZUMAB AND MYCOPHENOLATE MOFETIL IN COMBINATION WITH CORTICOSTEROIDS AND CYCLOSPORINE (LOW DOSE VERSUS LOW DOSE FOLLOWED BY WITHDRAWAL) TO OPTIMIZE RENAL FUNCTION IN RECIPIENTS OF RENAL ALLOGRAFTS

E. Calleja, B. Nashan, Y. Vanrenterghem, 2004 .

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

L. Gibiansky, K. Patel, Patrick F. Smith, 2020, British journal of clinical pharmacology.